Sign In
Buy CAR
$173.86
+1.48 (+0.86%)
At Close: Jun 03, 2026
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Avis Budget Group, Inc. ("Avis Budget" or "the Comp
SAN JOSE, Calif. , Feb. 14, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Avis Budget Group, Inc. ("Avis Budget") (NASDAQ:CAR) concerning possi
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Avis Budget Stock Price Decreases 7% Since Reporting Loss in Q4
01:21pm, Thursday, 13'th Feb 2025
CAR's top line in the fourth quarter of 2024 takes a hit as revenues in the Americas decline.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avis Budget Group, Inc. - CAR
12:15pm, Thursday, 13'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Avis Budget Group, Inc ("Avis Budget" or the "Company") (NASDAQ:CAR). Such investor
Avis Budget Group, Inc. (CAR) Q4 2024 Earnings Call Transcript
01:30pm, Wednesday, 12'th Feb 2025
Avis Budget Group, Inc. (NASDAQ:CAR ) Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ET Company Participants David Calabria - SVP, Corporate Finance and Treasurer Joseph Ferraro - Presiden
Avis Budget (CAR) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
07:01pm, Tuesday, 11'th Feb 2025
The headline numbers for Avis Budget (CAR) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street es
Avis Budget Group (CAR) Reports Q4 Loss, Misses Revenue Estimates
06:36pm, Tuesday, 11'th Feb 2025
Avis Budget Group (CAR) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to earnings of $7.10 per share a year ago.
Avis Budget Group Reports Fourth Quarter and Full Year Results
04:02pm, Tuesday, 11'th Feb 2025
PARSIPPANY, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced financial results for the fourth quarter and full year ended December 31, 2024 today.
CARsgen's First Enrolled Subject in the THANK-u Plus™ Platform-Based Allogeneic CAR-T Trial Achieves sCR at Week 4
07:29pm, Sunday, 09'th Feb 2025
SHANGHAI , Feb. 9, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies
Avis Budget Group to Announce Fourth Quarter 2024 Results on February 11th
03:51pm, Friday, 07'th Feb 2025
PARSIPPANY, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced today that it plans to report its fourth quarter 2024 results after the market close on Tuesday, Feb
5 Broker-Favorite Stocks to Keep an Eye on Amid Current Volatility
04:01pm, Monday, 03'rd Feb 2025
Investors should keep a tab on stocks like General Motors, Dana, Valero Energy, National Vision and Avis Budget for high returns.
Avis Budget Group (CAR) Expected to Beat Earnings Estimates: Should You Buy?
11:00am, Monday, 03'rd Feb 2025
Avis Budget (CAR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma.
